// App-Quantinova.ai

TPS628 : Diarrhea prevention and prophylaxis with crofelemer in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and docetaxel or paclitaxel with or without carboplatin.

Researchers

Presenter

  • Jennifer Gao

Principal Investigators

  • Ming Tony Tan

  • Sandra M. Swain

Medical Centers

  • National Cancer Institute at the National Institutes of Health, Rockville, MD

  • Georgetown University, Washington, DC

  • NSABP/NRG Oncology, and The Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Carboplatin

  • Trastuzumab

  • Paclitaxel

  • Crofelemer

  • Pertuzumab

  • Docetaxel

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved